No abstract

A novel, simple and economic reverse phase high performance liquid chromatography (RP-HPLC) method has been developed for the quantification of Meloxicam in bulk and tablet dosage form with greater precision and accuracy. Separation was achieved on Develosil ODS HG-5 RP C18, (15 cm × 4.6 mm i.d. 5 μm) column in isocratic mode with mobile phase consisting of acetonitrile: phosphate buffer(pH 3.4) (60:40) with a flow rate of 1 mL/min. The detection was carried out at 268 nm. The retention time of Meloxicam was found to be 2.09 min. The method was validated as per ICH guidelines. Linearity was established for Meloxicam in the range 20 – 120 μg/ml with R2 value 0.996. The percentage recovery of Meloxicam was found to be in the range 99.99-100.46%. The high recovery and low relative standard deviation confirm the suitability of the proposed method for the estimation of the drug in bulk and tablet dosage forms. Validation studies demonstrated that the proposed RP-HPLC method is simple, specific, rapid, reliable and reproducible for the determination of Meloxicam for Quality Control level.

No abstract

INTRODUCTIONLornoxicam((3E)-6-chloro-3-[hydroxy(pyridin-2ylamino)methylene]-2-methyl-2,3-dihydro- 4H-thieno[2,3e][1,2]thiazin-4-one 1,1-dioxide) is a non-steroidal antiinflammatory drug (NSAID) 1 . Lornoxicam is a compound in the same chemical class as piroxicam, meloxicam and tenoxicam with potent antiinflammatory, antipyretic and analgesic activity. Lornoxicam (chlortenoxicam), is a new nonsteroidal antiinflammatory drug (NSAID) of oxicam class. It is distinguished from established oxicams by a relatively short elimination halflife, lornoxicam inhibits the COX-1/COX-2 system, the production of interleukin-6 and the inducible NO synthase 2 . It may be applied by the intramuscular or intravenous route; its bioavailability after oral application is approximately 90 %. Although its elimination half-life is only about 4 h, the duration of effect is approximately 8 h, analogous to other acidic antipyretic analgesics. The analgesic potency of lornoxicam is remarkable. In doses of 16 mg (i.m.) its analgesic effect is comparable with that of 20 mg morphine (i.m.) or 50 mg tramadol (i.v.) 3 . It acts by nonselective inhibition of cyclooxygenase-1 and 2. It is prescribed for osteoarthritis, rheumatoid arthritis, acute lumbar sciatica conditions and postoperative